A Phase 1 interventional study of Pimasertib Capsule (Part A) and Pimasertib Tablet (Part A) in Neoplasms, sponsored by EMD Serono. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial extension phase).
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 38 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pimasertib Capsule (Part A) · Drug: Pimasertib Tablet (Part A) · Drug: Pimasertib Capsule (Part B and trial extension phase)
Drug: Pimasertib Tablet (Part A) · Drug: Pimasertib Capsule (Part A) · Drug: Pimasertib Capsule (Part B and trial extension phase)
Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
Also known as: AS703026, MSC1936369B
Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
Also known as: AS703026, MSC1936369B
Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
Also known as: AS703026, MSC1936369B
Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
Also known as: AS703026, MSC1936369B
Drug page: Pimasertib
Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
Also known as: AS703026, MSC1936369B
Maximum Observed Plasma Concentration (Cmax)
Maximum observed plasma concentration (Cmax) was calculated for Part A Pimasertib 60 mg Capsule and tablet.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Area Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t)
Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration was at or above the lower limit of quantification.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC0-inf)
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Apparent Terminal Half-life (t1/2)
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Apparent Total Body Clearance (CL/f)
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Apparent Volume of Distribution (Vz/f)
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Terminal Rate Constant (λz)
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug administration until 30 days after the last dose of study drug administration that were absent before treatment or that worsened relative to pre treatment state.
Time frame: From the first dose of study drug administration until 30 days after the last dose of study drug administration, assessed up to 14 Months
Part B: Number of Subjects Who Experienced Complete Response (CR)
CR as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 defined as disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to less than (\<)10 millimeter (mm).
Time frame: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months
Part B: Number of Subjects Who Experienced Partial Response (PR)
PR as per RECIST v1.1 defined as 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters.
Time frame: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months
Part B: Number of Subjects Who Experienced Stable Disease (SD)
SD as per RECIST v1.1 defined as neither shrinkage to qualify for PR nor increase to qualify for progressive disease (PD) taking the smallest sum diameters on study as reference. PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; PD = 20% increase in sum of diameters of target lesions; the appearance of \>=1 new lesions.
Time frame: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months
Part B: Number of Subjects Who Experienced Progressive Disease (PD)
PD as per RECIST v1.1 defined as 20% increase in sum of diameters of target lesions; the appearance of \>=1 new lesions.
Time frame: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months
First/last subject (informed consent): Nov 2013/Feb 2015. Clinical data cut-off: May 2014, Study completion date: Feb 2015
| Milestone | Part A: Pimasertib Capsule Then Pimasertib Tablet | Part A: Pimasertib Tablet Then Pimasertib Capsule | Part B:Pimasertib Capsule |
|---|---|---|---|
| Started | 21 | 17 | 0 |
| Completed | 21 | 17 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part A: Pimasertib Capsule Then Pimasertib Tablet | Part A: Pimasertib Tablet Then Pimasertib Capsule | Part B:Pimasertib Capsule |
|---|---|---|---|
| Started | 0 | 0 | 38 |
| Completed | 0 | 0 | 38 |
| Not completed | 0 | 0 | 0 |
Maximum observed plasma concentration (Cmax) was calculated for Part A Pimasertib 60 mg Capsule and tablet.
| nanogram per milliliter (ng/mL) | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 254.6 ± 75.7 | 314.1 ± 84.2 |
| h*ng/mL | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC0-inf) | 1110.3 ± 74.2 | 1109.2 ± 72.9 |
| hour | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0.750 (0.25 to 4.05) | 0.517 (0.25 to 3.93) |
| hour | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet |
|---|---|---|
| Apparent Terminal Half-life (t1/2) | 4.38 (1.65 to 8.15) | 4.47 (0.71 to 6.21) |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| liter per hour (L/h) | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet |
|---|---|---|
| Apparent Total Body Clearance (CL/f) | 54.041 ± 74.2 | 54.092 ± 72.9 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| Liter | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet |
|---|---|---|
| Apparent Volume of Distribution (Vz/f) | 346.454 ± 54.1 | 334.540 ± 59.0 |
| 1/h | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet |
|---|---|---|
| Terminal Rate Constant (λz) | 0.16 (0.09 to 0.42) | 0.15 (0.11 to 0.98) |
Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration was at or above the lower limit of quantification.
| hour*nanogram per milliliter (h*ng/mL) | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t) | 979.0 ± 76.5 | 1060.7 ± 73.0 |
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug administration until 30 days after the last dose of study drug administration that were absent before treatment or that worsened relative to pre treatment state.
| subjects | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet | Part B: Pimasertib Capsule |
|---|---|---|---|
| TEAEs | 19 | 20 | 38 |
| Serious TEAEs | 1 | 0 | 19 |
| TEAEs leading to discontinuation | 0 | 0 | 13 |
CR as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 defined as disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to less than (\<)10 millimeter (mm).
| subjects | Part B: Pimasertib Capsule |
|---|---|
| Part B: Number of Subjects Who Experienced Complete Response (CR) | 0 |
PR as per RECIST v1.1 defined as 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters.
| subjects | Part B: Pimasertib Capsule |
|---|---|
| Part B: Number of Subjects Who Experienced Partial Response (PR) | 1 |
SD as per RECIST v1.1 defined as neither shrinkage to qualify for PR nor increase to qualify for progressive disease (PD) taking the smallest sum diameters on study as reference. PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; PD = 20% increase in sum of diameters of target lesions; the appearance of \>=1 new lesions.
| subjects | Part B: Pimasertib Capsule |
|---|---|
| Part B: Number of Subjects Who Experienced Stable Disease (SD) | 10 |
PD as per RECIST v1.1 defined as 20% increase in sum of diameters of target lesions; the appearance of \>=1 new lesions.
| subjects | Part B: Pimasertib Capsule |
|---|---|
| Part B: Number of Subjects Who Experienced Progressive Disease (PD) | 15 |
Collected over Baseline up to end of trial (before the start of a new anticancer therapy or 30 ± 2 days after the last investigational medicinal product administration.). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Pimasertib 60 mg Capsule | — | 1/38 (2.6%) | 18/38 (47.4%) |
| Part A: Pimasertib 60 mg Tablet | — | 0/37 (0%) | 17/37 (45.9%) |
| Part B: Pimasertib Capsule (BID) | — | 19/38 (50%) | 37/38 (97.4%) |
| Event | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet | Part B: Pimasertib Capsule (BID) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/38 | 0/37 | 2/38 |
| PyrexiaGeneral disorders | 1/38 | 0/37 | 2/38 |
| HypertensionVascular disorders | 0/38 | 0/37 | 2/38 |
| HypotensionVascular disorders | 0/38 | 0/37 | 2/38 |
| Cardiac failure congestiveCardiac disorders | 0/38 | 0/37 | 1/38 |
| Abdominal pain upperGastrointestinal disorders | 0/38 | 0/37 | 1/38 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/38 | 0/37 | 1/38 |
| Rectal haemorrhageGastrointestinal disorders | 0/38 | 0/37 | 1/38 |
| Small intestinal obstructionGastrointestinal disorders | 0/38 | 0/37 | 1/38 |
| Disease progressionGeneral disorders | 0/38 | 0/37 | 1/38 |
| Event | Part A: Pimasertib 60 mg Capsule | Part A: Pimasertib 60 mg Tablet | Part B: Pimasertib Capsule (BID) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/38 | 6/37 | 22/38 |
| FatigueGeneral disorders | 2/38 | 0/37 | 20/38 |
| Blood creatine phosphokinase increasedInvestigations | 0/38 | 0/37 | 17/38 |
| NauseaGastrointestinal disorders | 3/38 | 2/37 | 13/38 |
| RashSkin and subcutaneous tissue disorders | 1/38 | 1/37 | 13/38 |
| Oedema peripheralGeneral disorders | 0/38 | 0/37 | 10/38 |
| Retinal detachmentEye disorders | 0/38 | 0/37 | 9/38 |
| VomitingGastrointestinal disorders | 1/38 | 0/37 | 9/38 |
| PyrexiaGeneral disorders | 1/38 | 0/37 | 8/38 |
| Vision blurredEye disorders | 1/38 | 4/37 | 7/38 |
Safety analysis set included all subjects who received at least one dose of investigational medicinal product (IMP).
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 60.6 ± 11.74 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 20 |
| Male | 18 |
Ran from Nov 2013 to primary completion in May 2014, 6 months.
Results were first posted in May 2016, 1 year 11 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 6 months is below that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pimasertib